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Abstract Infarctarterystentingwithadjunctiveabciximab
therapy is widely used treatment for patients with acute
myocardial infarction (AMI). However, bleeding compli-
cations have been associated with a worse clinical out-
come. Randomized trials in elective patients have shown
that postprocedural protamine administration is safe and
associated with a signiﬁcant reduction in bleeding com-
plications. The aim of the current study was to evaluate in
STEMI patients undergoing primary percutaneous coro-
nary intervention (PCI) with abciximab and stenting whe-
ther immediate reversal of anticoagulation by protamine is
safe and associated with a reduction in the occurrence of
bleeding complications. From January 2004 to June 2005,
254 patients with STEMI had immediate reversal of anti-
coagulation by protamine administration after infarct artery
stenting and received abciximab therapy without heparin
infusion (Group 1). These patients were compared with a
control group of 265 patients (June 2002–December 2003)
treated with the standard heparin therapy: bolus in order to
achieve an activated coagulation time of 250–300 s during
PCI plus 12-h infusion (7 UI/kg/h; Group 2). We excluded
patients undergoing IABP implantation. The two groups
were similar in all baseline characteristics. There were no
differences in in-hospital mortality, reinfarction, urgent
target vessel revascularization, stroke or acute or subacute
stent thrombosis, while Group 1 patients showed a lower
incidence of major bleeding complications (ACUITY
scale: 1.1 vs. 4.0%, P = 0.035) and a shorter length of
hospital stay (3.5 ± 1.7 vs. 4.0 ± 1.6 days, P = 0.002) as
compared with heparin treated patients. Among patients
undergoing primary stenting with abciximab administra-
tion, immediate post-PCI reversal anticoagulation by
protamine without associated heparin infusion is safe and
associated with a signiﬁcant reduction in major bleeding
complications.
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Introduction
Routine infarct artery stenting and abciximab as adjunctive
therapy is currently considered the preferred treatment for
patients with ST-segment elevation myocardial infarction
(STEMI) [1], notwithstanding the increased risk of bleed-
ing complications due to the associated anticoagulation
state produced by heparin. Post-procedure heparin infusion
was used in all the ﬁve concluded randomized trials [2–6]
of primary percutaneous coronary intervention (PCI)
comparing abciximab with placebo, and after the EPIC trial
[7] that showed an excess in bleeding in patients receiving
abciximab and heparin, in the other trials the dosage of
heparin infusion was lowered with subsequent bleeding
rate similar to the one of patients receiving heparin alone
without any decreased beneﬁt in terms of ischemic com-
plications. We hypothesized that the maintenance of an
anticoagulation state by heparin after PCI is a major
determinant of bleeding complications while has only
limited impact on the prevention of post-PCI ischemic
complications. Thus, we assessed the safety and efﬁcacy of
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PCI followed by abciximab 12-h infusion without associ-
ated heparin infusion.
Methods
Study population
From January 2004 to June 2005 a strategy of routine
reversal of anticoagulation state by protamine at the end of
primary PCI followed by 12-h abciximab infusion without
adjunctive heparin infusion was adopted. During this per-
iod a total of 310 patients underwent primary stenting with
abciximab administration. The clinical outcome of these
patients was compared with the one of a control group of
305 patients treated in the previous 18 months with stan-
dard heparin anticoagulation (bolus during PCI in order to
achieve an activated coagulation time of 250–300 s fol-
lowed by 12 h infusion during abciximab infusion (Group
2). Ninety-six patients (56 in the Group 1 and 40 in the
Group 2) who required intra-aortic pump implantation
during or after PCI or with suboptimal procedural success
(TIMI\3 or residual stenosis[50%) were excluded from
the analysis because of established need of heparin infu-
sion. Thus our ﬁnal population is represented by 254
patients in Group 1 and 265 patients in Group 2.
Criteria for primary PCI and infarct artery stenting with
adjunctive abciximab therapy were: (1) chest pain persist-
ing more than 30 min associated with ST-segment eleva-
tion of at least 0.1 mV in 2 or more contiguous
electrocardiographic leads, (2) admission within 12 h of
symptom, and (3) reference infarct artery diameter
C2.5 mm on visual assessment or smaller vessels with non-
optimal result after balloon angioplasty. Contraindications
for abciximab therapy were: previous ﬁbrinolytic therapy,
history of bleeding diathesis or allergy to the study drugs,
major surgery within 15 days, active bleeding.
Treatments
Before catheterization patients received 325 mg of aspirin
orally, or 250 mg intravenously. Abciximab (ReoPro,
Centocor, Malvern, PA) was administered immediately
before the procedure as a bolus of 0.25 mg/kg of body
weight followed by a 12-h infusion at a rate of 0.125 lg/
kg/min. Heparin was given as an initial bolus of 70 UI/kg,
and additional boluses were administered during the pro-
cedure to achieve an activated clotting time of 250–300 s.
Group 1 patients had reversal anticoagulation state (deﬁned
as activated clotting time\150 s) by the administration of
25–50 mg of protamine at the end of the procedure, while
Group 2 patients continued low dose heparin infusion
(7 UI/kg/h) for 12 h. Both groups had sheath removal
(femoral approach) at the end of the procedure, and
hemostasis was achieved by the use of closure devices or
manual compression after failure of closer device attempt.
Clopidogrel (300 or 600 mg) or ticlopidine (500 mg) was
administered after the procedure in all patients. Patients
were thereafter treated with aspirin (100 mg/day indeﬁ-
nitely), and clopidogrel (75 mg/day) or ticlopidine
(500 mg/day) for at least 3 months.
End-points and outcome measures
The primary safety end-point was the incidence of
in-hospital major adverse cardiac events (death from any
cause, nonfatal reinfarction, target vessel revascularization
and stroke), while the primary efﬁcacy end-point was the
incidence of major bleeding complications according to the
Acute Catheterization and Urgent Intervention Triage
strategY (ACUITY) scale [8]. Major bleedings were eval-
uated also according to the Thrombolysis In Myocardial
Infarction (TIMI) criteria [9]. Reinfarction was deﬁned as
recurrent chest pain with ST-segment or T-wave changes
and recurrent elevation of cardiac enzymes. Stent throm-
bosis was deﬁned as angiographic documentation of target
vessel occlusion or any death or reinfarction that is not
clearly related to causes other than stent occlusion. Target
vessel revascularization was deﬁned as coronary angio-
plasty or coronary surgery performed due to restenosis or
reocclusion of the infarct artery.
Statistical analysis
Discrete data are summarized as frequencies, while con-
tinuous as mean ± SD. Chi-square test analysis was used
for comparison of categorical variables. Student t test was
used to test differences among continuous variables. All
analyses were conducted according to the intention-to-treat
principle. A P value \0.05 was considered signiﬁcant.
Analyses were performed with SPSS for Windows, version
11.5 (SPSS Inc., Chicago, Illinois).
Results
The two groups were similar in all baseline clinical and
procedural characteristics (Table 1). Femoral access was
used in nearly all patients of both groups. Maintenance of
anticoagulation after PCI by heparin for at least 12 h in
Group 1 occurred in 15 patients (6%) based on operator’s
decision, while early discontinuation of heparin infusion
was observed in 11 patients (4%) of Group 2.
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There were no differences in the incidence of death,
myocardial infarction, target vessel revascularization and
stroke between groups during hospitalization (Table 2) and
at 6 months (Fig. 1). The cause of in-hospital death was
refractory heart failure in most cases of both groups while
one death occurred as a consequence of fatal reinfarction in
Group 2. In the analysis restricted to high-risk patients,
such as those ones with multivessel disease (n = 240), no
difference in in-hospital death (4.1 vs. 3.4%, P = 0.95) and
in acute or subacute stent thrombosis (0.8 vs. 0.8%,
P = 0.9) was observed between the two groups.
The incidence of in-hospital major bleeding was more
than threefold lower in Group 1 as compared to Group 2
(Table 3). Most of the major bleeding complications
occurred at the artery entry site, while fatal bleeding
occurred in one patient of Group 2. A trend towards a
decreased major bleeding rate was revealed using the more
stringent TIMI criteria (0.4 vs. 2.2%, P = 0.062). The
length of hospital stay was lower in Group 1 as compared
to Group 2 (3.5 ± 1.7 vs. 4.0 ± 1.6 days, P = 0.002).
Discussion
The EPIC study results [7] raised the important question
regarding the balance between hemorrhagic risk and clin-
ical beneﬁt with abciximab therapy and standard-dose
heparin during PCI. In the EPILOG Trial [10], abciximab
with a reduced-dose heparin treatment showed a lower
incidence of major bleeding complications as compared to
abciximab with a standard-dose heparin, without affecting
the effectiveness of the prevention of PCI ischemic com-
plications. However, bleeding complication after PCI and
adjunctive glycoprotein IIb/IIIa inhibition with anticoagu-
lant treatment remains a major issue with signiﬁcant impact
on short and long-term clinical outcomes [11]. Heparin has
Table 1 Baseline clinical and
procedural characteristics
TIMI Thrombolysis In
Myocardial Infarction
Abciximab alone
(n = 254)
Abciximab plus heparin
(n = 265)
P value
Age (years) 65 ± 13 65 ± 13 0.963
Male 185 (72%) 198 (75%) 0.526
Current smoker 102 (40%) 96 (37%) 0.428
Hypertension 123 (48%) 108 (41%) 0.137
Cholesterolemia[200 mg/dl 95 (37%) 110 (41%) 0.267
Diabetes mellitus 36 (14%) 42 (16%) 0.511
Previous myocardial infarction 21 (8%) 32 (13%) 0.152
Anterior infarct location 118 (46%) 112 (42%) 0.379
Cardiogenic shock 7 (3%) 3 (1%) 0.179
Multivessel disease 116 (45%) 115 (43%) 0.660
Preprocedural TIMI grade ﬂow 2–3 58 (23%) 60 (23%) 0.599
Time of ischemia, min 205 ± 124 188 ± 134 0.138
Infarct artery stenting 248 (98%) 260 (98%) 0.481
Table 2 Safety end-points
CK creatine kinase
a MACE major adverse cardiac
events (death or reinfarction or
target vessel revascularization)
Abciximab alone
(n = 254)
Abciximab plus heparin
(n = 265)
P value
In-hospital outcomes
Death 4 (1.6%) 4 (1.5%) 0.961
Reinfarction 2 (0.8%) 1 (0.4%) 0.538
Target vessel revascularization 1 (0.4%) 2 (0.8%) 0.264
Overall MACE
a 6 (2.4%) 7 (2.6%) 0.839
Stroke 2 (0.8%) 1 (0.4%) 0.538
Acute or subacute stent thrombosis 2 (0.8%) 1 (0.4%) 0.538
Peak CK value (U/L) 2466 ± 2331 2231 ± 2134 0.232
Time-to-peak CK (h) 7.2 ± 6.5 6.5 ± 3.6 0.465
Thrombocytopenia (\100 9 10
9/l) 0 (0%) 3 (1%) 0.089
Congestive heart failure 5 (2.0%) 11 (4.1%) 0.151
Hospitalization length (days) 3.4 ± 1.4 3.9 ± 1.6 0.0001
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123shortcomings such as indirect inhibition of antithrombin
III, which levels may be quite variable, and it bounds to
nonspeciﬁc circulating proteins. As a consequence the
response to the drug is unpredictable. Recent concluded
randomized Trials assessed different antithrombotic strat-
egies in order to reduce the incidence of bleeding without
increase in ischemic complications [12–14].
Since the ﬁrst documentation by Jaques [15], protamine
has been used clinically to promptly reverse the anticoag-
ulant effect of heparin. It must be recognized that prot-
amine is currently largely and safely used after heart
surgery, including patients receiving mechanical prosthe-
sis. However, reversal of heparin effect with the adminis-
tration of protamine may potentially induce hypotension,
platelet aggregation, and thrombus formation [16–18].
These fears have refrained from a larger application to
promote early sheath removal after PCI.
Several reports have investigated so far the safety of
routine application of protamine and early sheath removal
after coronary stenting. Pan et al. [19] randomized 228
patients after successful stent implantation to protamine
and in-laboratory sheath removal versus no protamine and
delayed sheath removal. No death and in-stent thrombosis
were observed in both groups, with shorter hospital stay in
patients receiving protamine. In a series of 429 consecutive
patients undergoing successful PCI (85% stenting), Ducas
et al. [20] showed that postprocedural protamine adminis-
tration and early sheath removal was safe with no case of
in-laboratory complications and no death at 30-day follow-
up, with very low rate of bleeding complications. The
safety of protamine administration has been shown by
Briguori et al. in 90 patients undergoing coronary stenting
[21].
Thuesen et al. [22] analyzed the safety and beneﬁts from
protamine administration and early sheath removal in a
very large cohort of patients undergoing elective PCI
between January 1999 and December 2002. There were
1.129 patients (Group 1) admitted between January 1999 to
December 1999, with sheath removal 4 h after the PCI
procedure, whereas 4.193 patients (Group 2), admitted
between January 2000 to December 2002, underwent
protamine sulphate administration and early sheath
removal. The rates of stent thrombosis, non-fatal myocar-
dial infarction and in-hospital mortality were similar in the
two groups. The rate of puncture site complications were
signiﬁcantly lower with protamine and early sheath
removal (2.6 vs. 4.7%, P\0.001). Finally, the safety of
heparin reversal by protamine, as compared to the short
half-life anticoagulant bivalirudin, has recently been shown
in our randomized trial including 850 patients undergoing
elective PCI [23].
Despite the safety of protamine administration largely
shown in elective successful stenting, no data have been so
far reported in patients with STEMI, where the risk of
thrombotic complications may be potentially higher than in
elective patients after rapid reversal of heparin.
However, it must be recognized that the HORIZONS
trial [14] has recently demonstrated that anticoagulation
therapy after successful primary PCI is no longer needed.
In this study more than 3000 STEMI patients undergoing
primary angioplasty were randomized to bivalirudin or
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Fig. 1 Six-month clinical outcome of patients receiving postproce-
dural protamine (Group 1, black bars) or 12-h heparin infusion
(Group 2, white bars)
Table 3 Major bleeding
complications
Abciximab alone
(n = 254)
Abciximab plus heparin
(n = 265)
P value
Major bleedings (ACUITY scale) 3 (1.1%) 11 (4.0%) 0.035
Intracranial bleeding 0 1
Access site hemorrage requiring intervention 0 1
C5 cm diameter hematoma 0 3
Reduction in hemoglobin concentration
of C4 g/dl without an overt source of bleeding
12
Reduction in hemoglobin concentration
of C3 g/dl with an overt source of bleeding
01
Use of any blood product transfusion 2 3
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123heparin and glycoprotein IIb-IIIa inhibitors. Since biva-
lirudin has a 25-min half-life, the risk of thrombotic
complications with bivalirudin would have expected to be
higher as compared to heparin plus glycoprotein IIb/IIIa
inhibitors. However, the slightly higher risk of early
(B24 h) stent thrombosis is explained by the suboptimal
inhibition of platelet aggregation as compared to adjunc-
tive administration of glycoprotein IIb–IIIa inhibitors.
Remarkably, bivalirudin was associated with a signiﬁcant
reduction in bleeding complications and a lower mor-
tality as compared to heparin plus glycoprotein IIb/IIIa
inhibitors.
To the best of our knowledge, this is the ﬁrst study
investigating the potential safety and beneﬁts of protamine
administration in patients undergoing primary angioplasty.
The results of this study show that post-PCI anticoagulation
reversal by protamine and routine abciximab therapy in
patients receiving primary infarct artery stenting is not
associated with an increase in ischemic complications
while the incidence of major bleeding is strongly reduced
and the length of in hospital stay signiﬁcantly shortened.
Notably, the incidence of acute and subacute stent throm-
bosis and of reinfarction was very low in both groups,
regardless of protamine administration. The results were
conﬁrmed in high-risk patients, such as those with mul-
tivessel disease.
Thus, the results of our study are consistent with those in
elective patients and exclude the hypothesis of a rebound
pro-thrombotic state after immediate heparin neutralization
due to heparin activated platelets or a heparin rebound with
reappearance of anticoagulant activity after protamine
administration.
Future randomized trials are certainly needed to inves-
tigate whether bivalirudin is still superior in terms of
mortality as compared to a strategy of heparin, abciximab
and early postprocedural sheath removal pending prot-
amine administration, in patients undergoing primary PCI
for STEMI in the era of new generation antiplatelets agents
[24–25].
Study limitations
Our results must be evaluated in the light of some study
limitations. This was a nonrandomized study. However,
only unselected and consecutive patients were enrolled,
and the two study groups were similar in baseline charac-
teristics. The shorter length of hospital stay of the more
recent group might be, at least in part, due to the fact that
the length of hospital stay for STEMI has decreased
worldwide in recent years. However, we adopted an early
discharge strategy before the beginning of study enrolment
and post-procedure heparin infusion was related to the
hospital stay length. The relatively small size may have
affected the results and made the study underpowered to
evaluate a strong endpoint, such as mortality. Postproce-
dural Heparin infusion is not recommended anymore, and it
might have favoured the beneﬁts observed in our study in
terms of bleeding complications with protamine adminis-
tration. A propensity score analysis was not performed,
being the groups homogeneous with no difference in
baseline characteristics, except than of Heparin infusion (as
per protocol).
Conclusions
The strategy of routine immediate reversal of anticoagu-
lation state after primary infarct artery stenting for STEMI
with routine abciximab as adjunctive therapy seems safe
and associated with a strong reduction in major bleeding
complications and with a shorter hospital stay. Thus, our
study, conﬁrming recent ﬁndings of the HORIZONS trial,
suggest that prolonged blood anticoagulation is not longer
needed after primary PCI, especially with adjunctive use of
glycoprotein IIb–IIIa inhibitors. However, future random-
ized trials are certainly needed to conﬁrm our ﬁndings and
to compare this strategy to the use of bivalirudin in the era
of new antiplatelet compounds.
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